Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31472591 | 0.97 | KDM1A (0.39) | LOXL2KDM1AKDM1BTAAR1RAD52 | |
| SCHEMBL28811818 | 0.84 | LOXL2 (0.33) | LOXL2KDM1AKDM1B | |
| SCHEMBL27846983 | 0.82 | TAAR1 (0.46) | LOXL2KDM1AKDM1BTAAR1HTR2A | |
| SCHEMBL1764604 | 0.78 | LOXL2 (0.43) | LOXL2TAAR1HRH3PNMTENPP2 | |
| SCHEMBL24357673 | 0.76 | KDM1A (0.37) | KDM1AKDM1B | |
| SCHEMBL19880893 | 0.76 | LOXL2 (0.42) | LOXL2TAAR1HRH3PNMTENPP2 | |
| SCHEMBL13527771 | 0.76 | LOXL2 (0.42) | LOXL2TAAR1HTR2AHRH3PNMT | |
| SCHEMBL855473 | 0.74 | ACHE (0.42) | KDM1AKDM1B | |
| SCHEMBL6302839 | 0.74 | MEP1B (0.41) | LOXL2TAAR1RAD52KMT2AENPP2 | |
| SCHEMBL22128462 | 0.74 | KDM1A (0.35) | KDM1AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028604-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-10654852-B2 | Antibiotics and methods of using same | THE BROAD INSTITUTE, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190240203-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING SAME | THE BROAD INSTITUTE, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| WO-2018075871-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING SAME | THE BROAD INSTITUTE, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-9809553-B2 | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-9809553-B2 | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-05-18 | — | — | US | disclosed |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-05-18 | — | — | US | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240203-A1 | NOVEL ANTIBIOTICS AND METHODS OF USING SAME | NRDC, TLR6, PEPD | LOXL2 2775/4885KDM1A 1907/4885KDM1B 2216/4885 |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | LOXL2 86/4885KDM1A 4126/4885KDM1B 4308/4885 |
| US-10654852-B2 | Antibiotics and methods of using same | NRDC, PEPD, TREH | LOXL2 3294/4885KDM1A 1434/4885KDM1B 1764/4885 |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MYLK, MYLK2, MYLK3 | LOXL2 2956/4885KDM1A 3673/4885KDM1B 3352/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | LOXL2 2878/4885KDM1A 91/4885KDM1B 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.